SCHEMBL30002937

SCHEMBL30002937

Cc1cc(C(C)Nc2ccccc2)c2oc(-c3ccncc3)cc(=O)c2c1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PIK3CA P42336 11/20 1.00
▸ PIK3CB P42338 4/20 1.00
▸ PIK3CD O00329 2/20 1.00
▸ PIK3CG P48736 2/20 1.00
▸ PRKDC P78527 2/20 0.57
▸ CFTR P13569 2/20 0.47
▸ CYP1A1 P04798 2/20 0.46
▸ CYP1A2 P05177 2/20 0.46
▸ CYP1B1 Q16678 2/20 0.46
▸ POLB P06746 1/20 0.46
▸ CSNK2A2 P19784 2/20 0.44
▸ CSNK2B P67870 2/20 0.44
▸ CSNK2A1 P68400 2/20 0.44
▸ MTOR P42345 1/20 0.44
▸ PIK3C3 Q8NEB9 1/20 0.44
▸ KDM4E B2RXH2 1/20 0.42
▸ ALDH1A1 P00352 1/20 0.42
▸ TP53 P04637 1/20 0.42
▸ CYP3A4 P08684 1/20 0.42
▸ MAPT P10636 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL909694 1.00 PIK3CA (1.00) PIK3CAPIK3CBPIK3CDPIK3CGPRKDC
SCHEMBL910161 0.89 PIK3CA (0.80) PIK3CAPIK3CBPIK3CDPIK3CGPRKDC
SCHEMBL13547022 0.87 PIK3CB (0.77) PIK3CAPIK3CBPIK3CDPIK3CGPRKDC
SCHEMBL910086 0.86 PIK3CB (0.76) PIK3CAPIK3CBPIK3CDPIK3CGPRKDC
SCHEMBL910282 0.86 PIK3CA (0.75) PIK3CAPIK3CBPIK3CDPIK3CGPRKDC
SCHEMBL25219256 0.85 PIK3CA (0.74) PIK3CAPIK3CBPIK3CDPIK3CGPRKDC
SCHEMBL30434657 0.85 PIK3CA (0.74) PIK3CAPIK3CBPIK3CDPIK3CGPRKDC
SCHEMBL3994804 0.84 PIK3CA (0.72) PIK3CAPIK3CBPIK3CDPIK3CGPRKDC
SCHEMBL3994533 0.83 PIK3CA (0.71) PIK3CAPIK3CBPIK3CDPIK3CGPRKDC
SCHEMBL25685461 0.82 PIK3CA (0.69) PIK3CAPIK3CBPIK3CDPIK3CGPRKDC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12247029-B2 Heterocyclic compounds as class II phosphoinositide 3-kinase inhibitors FORSCHUNGSVERBUND BERLIN E.V. (DE) 2025-03-11 — — US disclosed
EP-3802530-B1 HETEROCYCLIC COMPOUNDS AS CLASS II PHOSPHOINOSITIDE 3-KINASE INHIBITORS FORSCHUNGSVERBUND BERLIN EV (DE) 2024-05-29 — — EP disclosed
US-20220332717-A1 HETEROCYCLIC COMPOUNDS AS CLASS II PHOSPHOINOSITIDE 3-KINASE INHIBITORS FORSCHUNGSVERBUND BERLIN E.V. (DE) 2022-10-20 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12247029-B2 Heterocyclic compounds as class II phosphoinositide 3-kinase inhibitors PIK3CA, PIK3CD, PIK3C2B PIK3CA 1/4885PIK3CB 4/4885PIK3CD 2/4885
US-20220332717-A1 HETEROCYCLIC COMPOUNDS AS CLASS II PHOSPHOINOSITIDE 3-KINASE INHIBITORS PIK3CA, PIK3CD, PIK3C2B PIK3CA 1/4885PIK3CB 4/4885PIK3CD 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback